Qubit Pharmaceuticals is proud to announce the arrival of renowned researcher Dr. Alberto Prozzo as Head of Research and Development in Quantum Computing.

press release

Qubit Pharmaceuticals is proud to announce the arrival of renowned researcher Dr. Alberto Prozzo as Head of Research and Development in Quantum Computing.

Paris (France), November 7, 2023 – Qubit Pharmaceuticals, a deep technology company specializing in drug discovery through simulation and molecular modeling accelerated by hybrid HPC and quantum computing, announced the arrival of Dr. Alberto Prozzo as Head of Quantum Computing R&D. Alberto Prozzo, 45, is a renowned researcher with a distinguished career in both academia and industry.

An accomplished researcher with a PhD from the University of Bristol, Dr Protzo has a distinguished career spanning both academia and industry. His remarkable journey began with a Master’s degree in Computer Engineering at the University of Padua, where he achieved a rare distinction of 110/110 for his Master’s thesis.

After working in the chemical and pharmaceutical sectors, Dr. Pruzzo entered the academic world, eventually receiving a commendation from the Faculty of Science at the University of Bristol for his pioneering doctoral work in integrated quantum photonics. He later received a prestigious Royal Academy of Engineering Research Fellowship to help shape the future of quantum computing.

His impressive research portfolio includes advances such as machine learning techniques to enhance quantum tomography, multi-particle quantum walking in integrated photonics, and the development of quantum photonic chips capable of multiple entanglement modes. One of his most important contributions to the advancement of quantum algorithms dates back to 2013, when he wrote the seminal proposal for the variational quantum eigenvalue (VQE), which laid the foundation for the development of quantum computing solutions with broad applications in areas such as quantum chemistry and drug discovery.

Dr Protzo’s awards, including the Google Faculty Research Award, Gold Medal at the Humies Awards and Senior Research Associateship and Associate Professor position at RMIT University, highlight his significant contributions to the field of quantum technology.

With Dr. Pruzzo on board, Qubit Pharmaceuticals is poised to use quantum computing to drive innovation in the pharmaceutical sector. His visionary work promises a revolution in drug discovery and development.

Robert Marino, CEO, comments: We are pleased to welcome Dr. Alberto Prozzo to our team. His remarkable contributions to quantum computing have paved the way for success. With him, we are confident that we will achieve a quantum advantage in drug discovery and accelerate the development of better treatments for every target and every patient.

Jean-Philippe Picomal, CSO, commentsAlberto Prosso stands out as one of the most brilliant minds in quantum computing today. Having followed his career for many years, I am absolutely thrilled that he has decided to join us. His expertise, research and wealth of knowledge will undoubtedly play an essential role in advancing our mission to unlock the enormous potential of quantum-assisted drug design.

Alberto Prozzo, team leader in quantum computing, comments: I’ve seen the shift in quantum computing research from academia to industry, and it’s been an amazing shift. Choosing to join Qubit Pharmaceuticals was a simple decision, as their mission to accelerate the discovery of new small molecule drugs aligns with the potential impact of my quantum computing research. Additionally, Qubit Pharmaceuticals is part of a dynamic quantum computing ecosystem, and being part of this exciting network of new companies is a tremendous opportunity. The company’s commitment to fostering collaboration between the private sector and academia offers an excellent mix of opportunities, making it an ideal place for me.

Alberto Prozzo, Head of Quantum Computing R&D at Qubit Pharmaceuticals

About Qubit Pharmaceutical Company

Qubit Pharmaceuticals was founded in 2020 with the vision of co-developing, with pharmaceutical and biotechnology companies, new, more effective and safer medicines. Derived from the research work of five internationally renowned scientists – Louis Lagardere (Sorbonne University and CNRS), Mathieu Montes (CNAM), Jean-Philippe Picomal (Sorbonne University and CNRS), Jay Ponder (Washington University in St. Louis), Pengyu Ren (University of Texas (AUSTIN) – Qubit Pharmaceuticals is using its Atlas platform to discover new drugs through simulation and molecular modeling accelerated by hybrid HPC and quantum computing. The multidisciplinary team, led by CEO Robert Marino, and the founders are based in France at the Paris Saint-Cochin Incubator and in the US in Boston.
For more information, or to join an ambitious team, visit www.qubit-pharmaceuticals.com.

Press contacts

Qubit Pharmaceuticals
Charles Corbett [email protected] +33 6.28.93.03.06
Nicholas Daniels [email protected] – + 33 6.63.66.59.22